MICROSCOPY AND CELL ANALYSIS SHARED RESOURCE PROJECT SUMMARY Decoding mechanisms in cancer biology requires a fundamental understanding of the relationship between structure and function. This is especially important for assessing tissue/tumor cell context, and at the macomolecular level, for organelle function and integrity, and chromosome structure and behavior. The Microscopy and Cell Analysis Shared Resource (MIC) provides exceptionally maintained high-end equipment for optical and electron microscopy, cytometry and cell sorting, and provides the technical expertise for their use to Mayo Clinic Cancer Center (MCCC) members conducting clinical or basic science cancer research. This shared resource is heavily used with 161 MCCC members using the facility in 2017, from each of the MCCC sites. The facility operates 10 hours/day on weekdays and 6 hours/day on weekends for assisted use, and for most areas 24/7 for unassisted use. The MIC provides access, training, and expertise for a wide array of state- of-the-art light and electron microscopy instrumentation, and for cell sorting and analysis. Our portfolio of instrumentation allows MCCC members to image single molecules, in live cells and tissues, or fixed specimens at optical or electron microscopic resolution, to analyze image data files by a wide variety of image analysis and 3D reconstruction packages, and to perform multi-color flow analysis and sorting of fixed or live cells. We support advanced optical imaging techniques such as FRET, TIRF, PALM, multi-photon, and 3D serial electron microscopy, as well as state-of-the-art flow cytometry and cell sorting instrumentation and analysis methods. The facility has aggressively pursued instrumentation funding which has allowed us to recently obtain a Zeiss Elyra super-resolution microscope, and this past year, a FEI Apreo Serial Block Face Electron Microscope. The MIC also provides cyberinfrastructure for data analysis, transfer, and storage of extremely large image data sets.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-47
Application #
10113576
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-04-25
Project End
2024-02-29
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
47
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547
DuBois, Steven G; Mosse, Yael P; Fox, Elizabeth et al. (2018) Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res 24:6142-6149
Farber, Benjamin A; Lalazar, Gadi; Simon, Elana P et al. (2018) Non coding RNA analysis in fibrolamellar hepatocellular carcinoma. Oncotarget 9:10211-10227

Showing the most recent 10 out of 1129 publications